A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

NCT01005979 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic

Interventions

DRUG: Lenalidomide, Rituximab, and Cyclophosphamide

Sponsor

Emory University

Collaborators

[object Object]